Mycobacterium tuberculosis 19-kDa lipoprotein induces Toll-like receptor 2-dependent peroxisome proliferator-activated receptor γ expression and promotes inflammatory responses in human macrophages

Liu,Li; Liu,Jincheng; Niu,Guoqiang; Xu,Qianhong; Chen,Qiliang

doi:10.3892/mmr.2014.3070

Mycobacterium tuberculosis 19-kDa lipoprotein induces Toll-like receptor 2-dependent peroxisome proliferator-activated receptor γ expression and promotes inflammatory responses in human macrophages

Authors:
- Li Liu
- Jincheng Liu
- Guoqiang Niu
- Qianhong Xu
- Qiliang Chen
View Affiliations

Affiliations: Department of Tuberculosis Medicine, The Tuberculosis Prevention and Care Hospital of Shaanxi Province, Xi'an, Shaanxi 710100, P.R. China
Published online on: December 10, 2014 https://doi.org/10.3892/mmr.2014.3070
Pages: 2921-2926

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mycobacterium tuberculosis (M.tb) enhances its survival in macrophages by suppressing immune responses, in part through its complex cell wall structures. M.tb 19‑kDa lipoprotein (P19), a component of the complex cell wall structures of M.tb, is a Toll‑like receptor (TLR) agonist, and may induce immune responses through TLR2. Furthermore, the activation of peroxisome proliferator‑activated receptor γ (PPARγ) is also involved in M.tb‑induced immune responses in macrophages. In the present study, specific agonists/antagonists and siRNA were used to investigate the role of PPARγ in P19‑induced immune responses in human macrophages, including TLR2 activation, p38 phosphorylation and cytokine production. In the present study, PPARγ expression, p38 phosphorylation and cytokine production were upregulated following M.tb H37Rv infection or P19 treatment. By pretreating macrophages with a specific PPARγ agonist or antagonist, it was demonstrated that phosphorylation and IL‑6 production are modulated in macrophages by PPARγ activity. Following TLR2 knockdown in macrophages, the expression of PPARγ was significantly decreased in the presence or absence of P19 treatment. Furthermore, p38 phosphorylation and cytokine production were significantly reduced in TLR2 knockdown macrophages following P19 treatment. It was demonstrated in the current study that PPARγ was induced and activated by M.tb infection and that P19‑induced PPARγ expression, p38 phosphorylation and cytokine production in macrophages are dependent on TLR2. These findings suggest a role for PPARγ and TLR2 in P19‑induced p38 phosphorylation and cytokine production, thereby potentially influencing M.tb pathogenesis.

View Figures

View References

1	Kumar V, Abbas AK, Fausto N and Mitchell RN: Robbins Basic Pathology. 8th edition. Saunders Elsevier; Philadelphia, PA: pp. 516–522. 2007
2	Konstantinos A: Testing for tuberculosis. Aust Prescr. 33:12–18. 2010.
3	Szatmari I and Nagy L: Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function. EMBO J. 27:2353–2362. 2008. View Article : Google Scholar : PubMed/NCBI
4	Szanto A and Nagy L: Retinoids potentiate peroxisome proliferator-activated receptor gamma action in differentiation, gene expression, and lipid metabolic processes in developing myeloid cells. Mol Pharmacol. 67:1935–1943. 2005. View Article : Google Scholar : PubMed/NCBI
5	Szatmari I, Töröcsik D, Agostini M, et al: PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood. 110:3271–3280. 2007. View Article : Google Scholar : PubMed/NCBI
6	Braissant O, Foufelle F, Scotto C, Dauça M and Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 137:354–366. 1996.PubMed/NCBI
7	Rigamonti E, Fontaine C, Lefebvre B, et al: Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages. Arterioscler Thromb Vasc Biol. 28:932–939. 2008. View Article : Google Scholar : PubMed/NCBI
8	Almeida PE, Silva AR, Maya-Monteiro CM, et al: Mycobacterium bovis bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis. J Immunol. 183:1337–1345. 2009. View Article : Google Scholar : PubMed/NCBI
9	Bruns H, Meinken C, Schauenberg P, et al: Anti-TNF immunotherapy reduces CD8⁺ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest. 119:1167–1177. 2009. View Article : Google Scholar : PubMed/NCBI
10	Mohan VP, Scanga CA, Yu K, et al: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun. 69:1847–1855. 2001. View Article : Google Scholar : PubMed/NCBI
11	Dlugovitzky D, Bay ML, Rateni L, et al: Influence of disease severity on nitrite and cytokine production by peripheral blood mononuclear cells (PBMC) from patients with pulmonary tuberculosis (TB). Clin Exp Immunol. 122:343–349. 2000. View Article : Google Scholar : PubMed/NCBI
12	Al-Attiyah R, El-Shazly A and Mustafa AS: Comparative analysis of spontaneous and mycobacterial antigen-induced secretion of Th1, Th2 and pro-inflammatory cytokines by peripheral blood mononuclear cells of tuberculosis patients. Scand J Immunol. 75:623–632. 2012. View Article : Google Scholar : PubMed/NCBI
13	Jones SA, Scheller J and Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 121:3375–3383. 2011. View Article : Google Scholar : PubMed/NCBI
14	Silva LC, Ortigosa LC and Benard G: Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2:817–833. 2010. View Article : Google Scholar : PubMed/NCBI
15	Roach SK and Schorey JS: Differential regulation of the mitogen-activated protein kinases by pathogenic and nonpathogenic mycobacteria. Infect Immun. 70:3040–3052. 2002. View Article : Google Scholar : PubMed/NCBI
16	Senthil KA, Bansal K, Holla S, Verma-Kumar S, Sharma P and Balaji KN: ESAT-6 induced COX-2 expression involves coordinated interplay between PI3K and MAPK signaling. Mol Immunol. 49:655–663. 2012. View Article : Google Scholar
17	Lee SH, Kim DW, Back SS, et al: Transduced Tat-Annexin protein suppresses inflammation-associated gene expression in lipopolysaccharide (LPS)-stimulated Raw 264.7 cells. BMB Rep. 44:484–489. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
19	Surewicz K, Aung H, Kanost RA, Jones L, Hejal R and Toossi Z: The differential interaction of p38 MAP kinase and tumor necrosis factor-alpha in human alveolar macrophages and monocytes induced by Mycobacterium tuberculois. Cell Immunol. 228:34–41. 2004. View Article : Google Scholar : PubMed/NCBI
20	Andersson M, Lutay N, Hallgren O, Westergren-Thorsson G, Svensson M and Godaly G: Mycobacterium bovis bacilli Calmette-Guerin regulates leukocyte recruitment by modulating alveolar inflammatory responses. Innate Immun. 18:531–540. 2012. View Article : Google Scholar
21	Schlesinger LS, Bellinger-Kawahara CG, Payne NR and Horwitz MA: Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol. 144:2771–2780. 1990.PubMed/NCBI
22	Sánchez A, Espinosa P, García T and Mancilla R: The 19 kDa Mycobacterium tuberculosis lipoprotein (LpqH) induces macrophage apoptosis through extrinsic and intrinsic pathways: a role for the mitochondrial apoptosis-inducing factor. Clin Dev Immunol. 2012:9505032012. View Article : Google Scholar
23	Brightbill HD, Libraty DH, Krutzik SR, et al: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science. 285:732–736. 1999. View Article : Google Scholar : PubMed/NCBI
24	Straus DS and Glass CK: Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28:551–558. 2007. View Article : Google Scholar : PubMed/NCBI
25	Moraes LA, Piqueras L and Bishop-Bailey D: Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 110:371–385. 2006. View Article : Google Scholar
26	Mei CL, He P, Cheng B, Liu W, Wang YF and Wan JJ: Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways. Cell Biol Int. 33:301–308. 2009. View Article : Google Scholar
27	Liu YL, Lu J, Shi J, et al: Increased expression of the peroxisome proliferator-activated receptor gamma in the immune system of weaned pigs after Escherichia coli lipopolysaccharide injection. Vet Immunol Immunopathol. 124:82–92. 2008. View Article : Google Scholar : PubMed/NCBI
28	Pascual G, Fong AL, Ogawa S, et al: A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature. 437:759–763. 2005. View Article : Google Scholar : PubMed/NCBI
29	de Assis EF, Silva AR, Caiado LFC, et al: Synergism between platelet-activating factor-like phospholipids and peroxisome proliferator-activated receptor gamma agonists generated during low density lipoprotein oxidation that induces lipid body formation in leukocytes. J Immunol. 171:2090–2098. 2003. View Article : Google Scholar : PubMed/NCBI